Skip to main content
. 2025 Jan 3;5(1):72–82. doi: 10.21873/cdp.10414

Figure 1.

Figure 1

Prognostic impact of the change in psoas muscle index (PMI) on overall survival (OS) and progression-free survival (PFS) in patients with colorectal liver metastasis (CRLM). We conducted a Kaplan–Meier survival analysis, subdividing patients into the PMI reduction group (>5%) and the non-reduction group (≤5%). In patients with CRLM, the PMI reduction group had a significantly poorer prognosis compared with the non-reduction group in terms of OS (log-rank test, p<0.001, A). With respect to PFS, the PMI reduction group also had a significantly poorer prognosis (p=0.033, B). Although there was no significant correlation between the change in PMI and survival or disease progression in stable disease (SD)/progressive disease (PD) group at initial efficacy assessment (OS: E, PFS: F), the PMI reduction group had a significantly poorer prognosis compared to the non-reduction group in terms of both OS (log-rank test, p=0.0034, C) and PFS (p=0.037, D) in the partial response (PR) group at initial efficacy assessment.